HBV Vaccine Adjuvant Composition for Th1 and Th2 Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis B vaccines using aluminum hydroxide adjuvants primarily stimulate Th2 immune responses and fail to induce Th1 cell immunity, while CpG adjuvants have structural diversity and uncertain efficacy, necessitating improved adjuvant compositions for enhanced prophylactic effects.
Innovation Solution
A pharmaceutical composition combining hepatitis B virus surface antigen with an immunostimulatory mixture of aluminum adjuvant and CpG oligodeoxynucleotide, featuring specific motifs and weight ratios, to induce both humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If aluminum hydroxide adjuvant is used to enhance humoral immunity, then antibody production is improved, but Th1 cell immune response cannot be induced
Solution Approach 1:
The patent combines aluminum hydroxide adjuvant and CpG oligodeoxynucleotide in a single composition. Aluminum hydroxide provides Th2 and humoral immunity enhancement, while CpG-ODN induces Th1 cell immune response. The synergistic combination allows simultaneous activation of both Th1 and Th2 pathways, resolving the contradiction between antibody production and Th1 response induction.
Solution Approach 2:
The invention uses a composite adjuvant system comprising two distinct immunological components: aluminum hydroxide (an inorganic adjuvant) and CpG oligodeoxynucleotide (a synthetic oligonucleotide). This composite material approach enables the vaccine composition to elicit multiple types of immune responses (humoral, Th1, and Th2) that a single adjuvant cannot achieve alone.
2Adaptability or versatility
If CpG adjuvants are used to induce Th1 immune response, then cellular immunity is enhanced, but structural diversity leads to uncertain efficacy
Solution Approach 1:
The patent specifies precise parameters for the CpG oligodeoxynucleotide including sequence composition (containing 5'-TTCGTT-3' or 5'-TCGTCGTCG-3' motifs), molecular weight range (50-200 kDa), and weight ratio to aluminum hydroxide (10-200:37.5). By controlling these critical parameters, the invention ensures consistent and reliable Th1 immune response induction while maintaining the ability to combine with aluminum hydroxide for comprehensive immune protection.
3Reliability
If combined adjuvant system is used to improve immune response, then prophylactic efficacy is enhanced, but adjuvant composition complexity increases
Solution Approach 1:
The patent establishes specific parameter ranges for the combined adjuvant system: CpG-ODN weight ratio to aluminum hydroxide (10-200:37.5), CpG molecular weight (50-200 kDa), and sequence motifs (5'-TTCGTT-3' or 5'-TCGTCGTCG-3'). These defined parameters simplify the complexity by providing clear formulation guidelines while maintaining enhanced prophylactic efficacy through the synergistic combination of both adjuvants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined adjuvants provide a faster and more robust immune response, achieving higher antibody conversion rates and sustained levels compared to single-adjuvant systems, with a synergistic effect improving vaccine efficacy.
Implementation Method 1
can bind to TLR9 (Toll-like receptor 9) in cells, induce an immune response dependent on Th1 pathway
Implementation Method 2
aluminum hydroxide (Al(OH)3) as an adjuvant, which is able to enhance Th2 immune response and humoral immunity, and induce the body to produce and secrete protective antibodies
Data Source
AI summary
The present invention provides a pharmaceutical composition for preventing hepatitis B virus infection and use thereof. The pharmaceutical composition comprises i) a hepatitis B virus surface antigen, a fragment thereof with antigenic activity and/or a variant thereof with antigenic activity; and ii) an immunostimulatory composition, which comprises an aluminum adjuvant and a CpG oligodeoxynucleotide, wherein the sequence of the CpG oligodeoxynucleotide comprises two or more copies of 5′-TTCGTT-3′ motif or 5′-TCGTCGTCG-3′ motif. The experimental results show that the components contained in the immunostimulatory composition can have a synergistic effect, thereby greatly enhancing the immune effect on hepatitis B virus surface antigen; only two immunizations can produce a good immune effect, and produce the antibody earlier than the existing vaccines and maintain a high level of antibody titer for a longer time.